ProCE Banner Activity


Targeted Therapy Comes to AML: Now What?


Join expert faculty for a 90-minute interactive program on the increasingly individualized treatment landscape for patients with acute myeloid leukemia (AML) considering their specific clinical and disease presentation characteristics. Also learn about important and promising ongoing clinical trials testing investigational therapeutic approaches for patients with relapsed or refractory AML, a disease setting that remains a challenging area of unmet need. Finally, gain practical insights on managing key adverse events with newer therapies available for patients with AML along with clinical pearls on how you can help your patients adhere to their oral medication regimens.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credit

Nurse Practitioners: 1.50 Nursing contact hours, includes 1.50 hour of pharmacotherapy credit

Released: September 28, 2022

Expiration: September 27, 2023

No longer available for credit.



Melissa Dove

Melissa Dove, MSBS, PA-C

Physician Associate
TriHealth Cancer Institute
Cincinnati, Ohio

Natasha L. Johnson

Natasha L. Johnson, MSN, APRN, AOCNP

Malignant Hematology APP Clinic Lead
Moffitt Cancer Center and Research Institute
Tampa, Florida


This activity is supported by an educational grant from AbbVie Inc.

Provided by

ProCE Banner


AbbVie Inc.

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe current recommendations for risk stratification and molecular testing in AML

  • Summarize evidence supporting the appropriate use of novel therapies in AML

  • Apply recommended strategies to identify and manage toxicities of novel therapies in AML


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Natasha L. Johnson, MS, ARNP, AOCNP: consultant/advisor/speaker: Abbvie, Taiho.

Melissa Dove, MSBS, PA-C, has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PACE staff have any relevant financial relationships to disclose.

Instructions for Credit

Learners wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.50 hours.

Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of 67%.

Release date: September 28, 2022
Expiration date: September 27, 2023


Interactive, audio-enhanced slide lecture


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Partners for Advancing Clinical Education (PACE), Practicing Clinicians Exchange, or any educational supporter.


Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Natasha L. Johnson, MS, ARNP, AOCNP, Moffitt Cancer Center, Tampa, Florida
Nursing contact hours: 1.50, which includes 1.50 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until September 27, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Melissa Dove, MSBS, PA-C, TriHealth Cancer Institute, Cincinnati, Ohio

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.